Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
Sumitomo Dainippon Pharma will make its third attempt for a PIII trial of its atypical antipsychotic lurasidone, sold as Latuda overseas, to obtain data to seek approval in Japan for the treatment of schizophrenia, President Masayo Tada revealed on October…
To read the full story
Related Article
- Latuda to Finally Hit Japan Market on June 11
June 5, 2020
- After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
BUSINESS
- Viatris Recalls Sevoflurane Anesthetic over Manufacturing Deviation
August 3, 2026
- Belite Bio Japan Launches Stargardt Disease Awareness Initiative
August 3, 2026
- Otsuka Eyes 3.5 Trillion Yen Sales by 2035 on New Growth Drivers
August 3, 2026
- Daiichi Sankyo Cuts FY2027 Net Profit Outlook on Higher Tax Burden
August 3, 2026
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…